Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 19;6(1):vdae187. doi: 10.1093/noajnl/vdae187

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

PMC Copyright notice

Figure 2. — Dose-response validation of selected ion channel modulators in patient-derived glioblastoma cell lines. Dose-response was validated for (A) flunarizine-2HCl, (B) SKF96365, (C) niguldipine, and (D) DPI-201-106 in 3 patient-derived glioblastoma cell lines. (E) GBM6 cells were treated with DMSO, flunarizine-2HCl, niguldipine, SKF96365, or DPI-201-106 for 7 days to analyze levels of apoptosis by flow cytometry. Data shown are mean ± SD, and statistical significance was determined with a 1-way ANOVA and Dunnett’s multiple comparison test. Dose-response curves of (F) SKF96365 and (G) DPI-201-106 were validated in 5 additional patient-derived primary glioblastoma cell lines. *P < .05, **P < .01.